Itraconazole has been reported to degrade and inhibit C1GALT1 protein in head and neck cancer [24], suggesting that this drug could mimic the antiproliferative effect of C1GALT1 knockdown and thus potentially serve as a prototype therapeutic agent for osteosarcoma. This evidence concerns the gene C1GALT1 and head and neck cancer.